Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Tundra lists 1 Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07523555

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After central antigen co-expression screening, participants are assigned to the most appropriate active dual-target module: CD19/CD22, CD19/CD20, BCMA/CD19, BCMA/CD38, BCMA/GPRC5D, CD33/CD123, CD33/CLL1, or CD5/CD7. Phase 1 determines safety, dose-limiting toxicities, and the recommended phase 2 dose for each module; phase 2 estimates preliminary antitumor activity, including overall response rate and MRD-negative response. Lymphodepletion with fludarabine/cyclophosphamide precedes infusion. The design is intended to reduce antigen escape by matching disease biology and target co-expression to a rational dual-target strategy.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-04-13

1 state

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL

Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia